

Anthony M. Casapao, Pharm.D., M.P.H.

University of Florida College of Pharmacy
580 W. 8th Street, Jacksonville, FL 32209
T: (904) 244-9129 E: Casapao@cop.ufl.edu

Education

Master in Public Health concentration in Epidemiology and Biostatistics 2016 – 2018
Harvard University School of Public Health – Boston, Massachusetts

Doctor of Pharmacy, *Cum Laude* 2005 – 2009
Wingate University School of Pharmacy – Wingate, North Carolina

Bachelor of Science in Biomedical Science, *Magna Cum Laude* 2003 – 2005
Midwestern University – Glendale, Arizona

Associate in Science 2000 – 2003
College of Lake County – Grayslake, Illinois

Professional Experience

Clinical Assistant Professor of Pharmacotherapy and Translational Research Oct 2017– Present
University of Florida College of Pharmacy – Jacksonville, FL
Department Chair: Reginald Frye, Pharm.D., Ph.D. FCCP
Divisional Chair: Kalen Manasco, Pharm.D., BCPS, FPPAG

Assistant Professor of Pharmacy Practice April 2014 – October 2017
Husson University School of Pharmacy – Bangor, ME
Chair: Ronald C. Reed, Pharm.D., FCCP, FAES

Pharmacotherapy Infectious Diseases Outcomes Research Fellow August 2011– March 2014
Fellowship Program (ACCP Peer Reviewed)
Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences – Detroit, MI
Fellowship Directors: Michael J. Rybak, Pharm.D., MPH, FCCP, FIDSA & Susan L. Davis, Pharm.D.

Post Graduate Year-2 Infectious Diseases July 2010 – July 2011
Residency Program (ASHP-Accredited)
University of Pittsburgh Medical Center – Pittsburgh, PA
Residency Director: Brian A. Potoski, Pharm.D., BCPS AQ-ID

Post Graduate Year-1 Pharmacy Practice June 2009 – July 2010
Residency Program (ASHP-Accredited)
St. Vincent's Medical Center – Jacksonville, FL
Residency Director: Michele Loudy, Pharm.D., BCPS

Adjunct Instructor August 2011– March 2014
Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences
Mentor: Michael J. Rybak, Pharm.D., MPH, FCCP, FIDSA & Susan L. Davis, Pharm.D.

Adjunct Instructor Teaching Certificate September 2010 – June 2011
 University of Pittsburgh School of Pharmacy – Pittsburgh, PA
 Program Director: Denise L. Howrie, Pharm.D.

Adjunct Instructor Teaching Certificate July 2009 – July 2010
 University of Florida College of Pharmacy – Jacksonville, FL
 Program Director: Lisa D. Inge, Pharm.D., BCPS, AAHIVE

Pharmacy Intern Summer 2007
 Harris Teeter Store #129 – Indian Trail, North Carolina
 Pharmacy Manager: Kevin Pultorak, R.Ph.

Pharmacy Technician 2001 – 2003
 Highland Park Hospital, an Evanston Northwestern Hospital – Highland Park, IL
 Pharmacy Director: Mike Sura, Pharm.D.

Pharmacy Technician 2000 – 2002
 Walgreen’s Pharmacy – Libertyville, Illinois
 Pharmacy Manager: Lowell Sederstrom, R.Ph.

Clinical Experience

Infectious Disease Specialist June 2018 – Present
 Department of Pharmacy, University of Florida Health Jacksonville, Jacksonville, Florida

Health Care-Associated Infection Advisory Board Member January 2018 – Present
 Division of Disease Control & Health Protection, Florida Department of Health, Tallahassee, FL

Clinical Infectious Diseases Pharmacotherapy Specialist September 2014 – October 2017
 Antimicrobial Stewardship Committee and Infection Prevention and Control Function Team
 Department of Pharmacy, Eastern Maine Medical Center, Bangor, Maine

HAI Collaborating Partners Committee: Pharmacy Member July 2015 – October 2017
 Maine Center for Disease Control and Prevention, Augusta, Maine

Rotation	Preceptor	Duration
Infectious Diseases Pharmacotherapy Research Outcomes Fellowship		
Infectious Diseases Consult	Michael J. Rybak, Pharm.D., MPH	30 weeks
PGY-2 Infectious Diseases Pharmacotherapy Residency		
Infectious Diseases Consult	Brian A. Potoski, Pharm.D., BCPS AQ-ID	32 weeks
Antibiotic Stewardship	Greg Eschenauer, Pharm.D., BCPS	4 weeks
Clinical Microbiology	A. William Pasculle, Sc.D.	8 weeks
Research Microbiology	Yohei Doi, MD, PhD	8 weeks
Antibiotic Management	Greg Eschenauer, Pharm.D., BCPS	Longitudinal
PGY-1 Pharmacy Practice Residency		
Critical Care & ID	Yasi Homayouni, Pharm.D.	4 weeks
Quality Management	Charzetta James, Pharm.D., MBA	4 weeks
Emergency Medicine	Sarah Hayes, Pharm.D.	4 weeks
Pharmacy Management	Karen Rehmer, R.Ph.	Longitudinal
Pharmacy Operations	Karen Rehmer, R.Ph.	4 weeks

PGY-1 Pharmacy Practice Residency cont.

Pharmacy Management	Adam N. Bauman, M.S., R.Ph.	4 weeks
Family Medicine	Michele Loudy, Pharm.D., BCPS	4 weeks
Quality Management	Charzetta James, Pharm.D., MBA	Longitudinal
Oncology	Robin Bettman, R.Ph., BCOP	4 weeks
Internal Medicine II	Michele Loudy, Pharm.D., BCPS	4 weeks
Infectious Diseases	Kevin Epps, Pharm.D.	4 weeks
Formulary Management	Lauren Stafford, Pharm.D., BCPS	Longitudinal
Drug Information	Lauren Stafford, Pharm.D., BCPS	4 weeks
Critical Care	John Totty Johnson, R.Ph.	4 weeks
Internal Medicine	Victoria Evelyn, Pharm.D.	4 weeks
Pharmacy Administration	Adam N. Bauman, M.S., R.Ph.	Longitudinal

Peer-Reviewed Publications

Piccirro, SR, **Casapao AM**, Claudio AM, Isache C, Jankowski CA. Comparison of acute kidney injury in patients prescribed vancomycin in combination with piperacillin-tazobactam or cefepime for diabetic foot infections. *Submitted to J Investig Med in September 2020 and under review.*

Jankowski CA, **Casapao AM**, Siller S, Isache C, Vahdat K, Claudio AM, Brown M, Feldhammer M. Capillary blood sampling is reliable methods for therapeutic drug monitoring of vancomycin. *Submitted to J Appl Lab Med in April 2020 and accepted for publication.*

Shoulders B, **Casapao AM**, Venugopalan V. An Update on Existing and Emerging Data for Meropenem-Vaborbactam. *Clin Ther.* 2020 Apr;43(4):692-702.

Egelund EF, **Casapao AM**. Pet Nemo's Pills – The Last Loophole in Antimicrobial Stewardship? *Clin Infect Dis.* 2019 Jan 1;70(1):177-179.

Ortwine JK, Zasowski EJ, Pogue JM, Hanni C, Giuliano C, **Casapao AM**, Mynatt R, Rybak MJ. Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's Complicated. *Infect Dis Ther.* 2019 Dec;8(4):627-640.

Allen JM, Bakare L, **Casapao AM**, Klinker K, Childs-Kean LM, Pomputius AF. Cefazolin versus Anti-Staphylococcal Penicillins for the Treatment of Patients with Methicillin-Susceptible Staphylococcus aureus Infection: A Meta-Analysis with Trial Sequential Analysis. *Infect Dis Ther.* 2019 Dec;8(4):671-686.

Claeys KC, Zasowski EJ, Trinh TD, **Casapao AM**, Pogue JM, Bhatia N, Mynatt RP, Wilson SS, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Rieck C, Johnson LB, Murray KP, Gordon J, Reyes K, Hartman P, Davis SL, Rybak MJ. Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline fosamil versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant *Staphylococcus aureus*. *Infect Dis Ther.* 2019 June;8(2):199-208.

Dilworth TJ, **Casapao AM**, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, Mercier RC. Adjuvant Beta-lactam Therapy Combined with Vancomycin for Methicillin-Resistant *Staphylococcus aureus* Bacteremia: Does Beta-lactam class matter? *Antimicrob Agents Chemother.* 2019 Mar;63(3):e02211-18.

Trinh TD, Zasowski EJ, Claeys KC, **Casapao AM**, Compton M, Lagnf A, Kidambi SD, Levine DP, Rybak MJ. Role of Vancomycin Minimum Inhibitory Concentration by Modified Population Analysis Profile Method in High Inoculum Methicillin-Resistant *Staphylococcus aureus* Infections. *Infect Dis Ther* 2018 Mar;7(1):161-9.

Jacobs DM, Dilworth TJ, Beyda NE, **Casapao AM**, Bowers DR. Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: A Multi-institutional Study. *Antimicrob Agents Chemother*. 2017 Dec 21;62(1), pii: e01464-17.

Casapao AM, Jacobs DM, Bowers DR, Beyda NE, Dilworth TJ. Early Administration of Adjuvant β -lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infection: A Retrospective, Multicenter Analysis. *Pharmacotherapy*. 2017 Nov;37(11):1347-56.

Zasowski EJ, Trinh TD, Claeys KC, **Casapao AM**, Sabagha N, Lagnf AM, Klinker KP, Davis SL, Rybak MJ. A Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. *Antimicrob Agents Chemother*. 2017 Jan;61(2). pii:e0215-16.

Bosso JA, **Casapao AM**, Edwards J, Klinker K, McCoy C, Nicolau DP, Perez KK, Marcarelli A, Dua D. Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion. *Hosp Pract (1995)*. 2016 Oct;44(4):183-189.

Claeys KC, Zasowski EJ, **Casapao AM**, Lagnf AM, Nagel JL, Nguyen CT, Hallesy J, Compton MT, Kaye KS, Levine DP, Davis SL, Rybak MJ. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. *Antimicrob Agents Chemother*. 2016 Sep 23;60(10):5841-8.

Lagnf AM, **Casapao AM**, Claeys KC, Rybak MJ. Comparison of Clinical Outcomes and Risk Factors in Polymicrobial versus Monomicrobial Enterococcal Bloodstream Infections. *Am J Infect Control* 2016; Aug;44(8):917-21.

Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ. Association Between Vancomycin Day 1 Exposure Profile and Outcomes Among Patients with Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. *Antimicrob Agents Chemother*. 2015 Jun;59(6): 2978-85.

Claeys KC, Smith JR, **Casapao AM**, Mynatt RP, Avery L, Shroff A, Yamamura D, Davis SL, Rybak MJ. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant *Staphylococcus aureus* infections. *Antimicrob Agents Chemother*. 2015 Apr;59(4):1969-76.

Sakoulas G, Moise PA, **Casapao AM**, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebricht JR, Nizet V. Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia using Daptomycin Plus Ceftaroline. *Clin Ther*. 2014 Oct 1;36(10):1317-33.

Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, Levine DP, Rybak MJ. Evaluation of Vancomycin Population Analysis Profile Susceptibility as a Predictor of Patient Outcomes with Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. *Antimicrob Agents Chemother*. 2014 Aug;58(8):4636-41.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. A Large Multicenter Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy for Severe Infections. *Antimicrob Agents Chemother.* 2014 May;58(5):2541-6.

Kullar R, **Casapao AM**, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. A Multicentre Evaluation of the Effectiveness and Safety of High-Dose Daptomycin for the Treatment of Infective Endocarditis. *J Antimicrob Chemother.* 2013 Dec;68(12):2921-6.

Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections. *Antimicrob Agents Chemother.* 2013 Sep;57(9):4190-6.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, LaPlante KL, Potoski BA, Rybak MJ. Clinical outcomes in patients with heterogeneous vancomycin-intermediate *Staphylococcus aureus* (hVISA) bloodstream infection. *Antimicrob Agents Chemother.* 2013 Sep;57(9):4252-9.

Casapao AM, Steed ME, Levine DP, Rybak MJ. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. *Expert Opin Pharmacother.* 2012 Jun;13(8):1177-86.

Abstracts

Kunz Coyne AJ, **Casapao AM**, Isache C, Morales J, McCarter YS, Jankowski CA. Influence of antimicrobial stewardship and molecular rapid diagnostic test on antimicrobial prescribing for extended-spectrum beta-lactamase and carbapenemase-producing bacteria in bloodstream infections. 9th Annual IDweek Meeting, October 2020.

Carr A, Minor S, El Ghali, Kaur P, **Casapao AM**. Early real-world evidence in the use of eravacycline therapy for the management of draconian infections. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 2020; Abstract #4006. 9th Annual IDweek Meeting, October 2020.

Wungwattana M, Mangino M, Ben G, Stogsdill P, **Casapao AM**. Does early de-escalation to anti-staphylococcal beta-lactams impact the duration of bacteremia in patients with methicillin-susceptible *Staphylococcus aureus* endocarditis? 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 2020; Abstract #3049.

Venugopalan V, Hernandez S, DeSear K, Peloquin C, Cherabuddi K, **Casapao AM**. Use of therapeutic drug monitoring to optimise cephazolin dosing in the treatment of methicillin-susceptible *Staphylococcus aureus* bacteremia. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 2020; Abstract #2657.

Nilles L, Pirasteh A, Sothoron C, Tucker C, **Casapao AM**. Effectiveness of Using Oral Vancomycin as Prophylaxis for *Clostridium difficile* Infections in High-Risk Patients. Florida Residency Conference, Tampa, Florida, May 2019. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 2020; Abstract #3676.

Cawoski HC, Johnson B, Stamper B, **Casapao AM**, Jankowski CA. A retrospective study comparing the clinical and economic outcomes of injection drug users versus non-injection drug users with endocarditis at a tertiary care center. Florida Residency Conference, Tampa, Florida, May 2019.

Bakare L, **Casapao AM**, Klinker KP, Childs-Kean LM, Pomputius AF, Allen JM. Cefazolin versus Anti-staphylococcal Penicillins for the Treatment of Patients with *Staphylococcus aureus* infection: A Meta-Analysis. 32nd Annual UF College of Pharmacy Research Showcase, Gainesville, Florida, February 2019.

Dilworth TJ, **Casapao AM**, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, Mercier RC. Adjuvant Beta-lactam Therapy Combined with Vancomycin for Methicillin-Resistant *Staphylococcus aureus* Bacteremia: Does Beta-lactam class matter? 56th Annual Infectious Diseases Society of America Conference combined with 7th Annual IDweek Meeting, San Francisco, California, October 2018; Abstract #70673.

Lee S. Jones SJ. **Casapao AM**. Empiric antimicrobial therapy and readmission to the emergency department in patients with urinary tract infections. 52nd Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Orlando, Florida, December 2017; Abstract #12-042. *Encore presentation*: 38th Annual Eastern States Conference, Hersey, Pennsylvania, May 2018. 56th Annual Infectious Diseases Society of America Conference combined with 7th Annual IDweek Meeting, San Francisco, California, October 2018; Abstract #73171.

Thomas LO, Jones SJ, **Casapao AM**. Adherence to empiric treatment recommended by IDSA/PIDS pediatric community-acquired pneumonia (CAP) guidelines according to immunization status. 52nd Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Orlando, Florida, December 2017; Abstract #12-043. *Encore presentation*: 38th Annual Eastern States Conference, Hersey, Pennsylvania, May 2018. 56th Annual Infectious Diseases Society of America Conference combined with 7th Annual IDweek Meeting, San Francisco, California, October 2018; Abstract #72739.

Rusby MLM, **Casapao AM**. Decision analysis and cost-effectiveness analysis of antibiotic prescribed for COPD patients with acute exacerbation at a primary care setting. 52nd Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Orlando, Florida, December 2017; Abstract #12-056.

Jacobs DM, Dilworth TJ, Beyda ND, **Casapao AM**, Mashtare T, Bowers DR. Characterization of Candiduria Treatment: A Multi-Institutional Study. 117th American Society for Microbiology Microbe Conference, New Orleans, Louisiana, June 2017; Abstract #4041.

Casapao AM, Mahlen SD. Evaluation of Ceftaroline and Telavancin Susceptibilities against Enterococcal Bloodstream Isolates. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #4328.

Casapao AM, Wungwattana M. The landscape of *Pseudomonas aeruginosa* clinical isolates in rural Northeastern United States and the Potential Impact on Hospital Mortality. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #7097.

Casapao AM, Mahlen SD. Ceftazidime-avibactam and ceftolozane-tazobactam activity against *Escherichia coli* producing CTX-M beta-lactamases. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #5215.

Kelley K, Nikornpan K, **Casapao AM.** Evaluation of Nephrotoxicity during Treatment with Vancomycin in Combination with Piperacillin-Tazobactam, Cefepime, or Meropenem. 8th Annual Husson Research and Scholarship Day, Bangor, Maine, April 20, 2017; Abstract #O-4.

Ravin K, **Casapao AM.** Effect of hospital stay duration in patients treated with aztreonam vs cefepime for gram negative empiric therapy: interim analysis. 51st Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 2016; Abstract #2-160 and 8th Annual Husson Research and Scholarship Day, Bangor, Maine, April 20, 2017; Abstract #PP-2.

Laliberte NF, Ki MJ, **Casapao AM,** Wungwattana M. Susceptibility of *Pseudomonas aeruginosa* bloodstream isolates in Maine and the implications for selection of empiric antibiotic regimens. 51st Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 2016; Abstract #2-179.

Rusby MLM, **Casapao AM.** Implementation of a pediatric antimicrobial stewardship in a primary care setting. 51st Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 2016; Abstract #12-010.

Roy B, Owsiak R. **Casapao AM.** Statewide prevalence of Carbapenem-resistant Enterobacteriaceae from the first full year of required reporting through the Notifiable Conditions Rule. Maine Center for Disease Control and Prevention 2016 Division of Infectious Disease Annual Conference, Augusta, Maine, November 16, 2016; Abstract #11.

Casapao AM, Grieser H, Meak S, Matluck N. Clinical Impact of Further Laboratory Diagnosis for Carbapenem Resistant Enterobacteriaceae. Maine Center for Disease Control and Prevention 2016 Division of Infectious Disease Annual Conference, Augusta, Maine, November 16, 2016; Abstract #5.

Zasowski EJ, Trinh TD, Claeys KC, **Casapao AM,** Rybak MJ. Predictors of Heterogenous Vancomycin-Intermediate *Staphylococcus aureus* among Patients with Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. 116th American Society for Microbiology Microbe Conference in conjunction with 56th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, June 2016; Abstract #436-4.

Ki MJ, Wilson C, Wungwattana M, Malen SD, **Casapao AM.** Evaluation of Ceftolozane/Tazobactam Susceptibilities of *Pseudomonas aeruginosa* Blood Isolates at Two Major Tertiary Referral Medical Centers. 116th American Society for Microbiology Microbe Conference in conjunction with 56th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, June 16-20, 2016; Abstract #259.

Wungwattana M, Malen SD, **Casapao AM.** Susceptibility of *Pseudomonas aeruginosa* Bloodstream Isolates to Ceftazidime-Avibactam in Northeastern United States. 116th American Society for Microbiology Microbe Conference in conjunction with 56th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, June 2016; Abstract #257.

Saab M, **Casapao AM**. Antibiotic Use in Acute Bacterial Skin and Skin Structure Infections. 7th Annual Husson Research and Scholarship Day, Bangor, Maine, April 21, 2016; Abstract #O-7.

Zasowski EJ, Trinh TD, Claeys KC, **Casapao AM**, Sabagha N, Hallesy J, Rybak MJ. Relationship between Duration of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infection and Mortality. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 2016; Abstract #6407.

Zasowski EJ, Trinh TD, Claeys KC, **Casapao AM**, Sabagha N, Rybak MJ. Ceftaroline Fosamil for the Treatment of Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 2016; Abstract #6408.

Leichtweis CL, **Casapao AM**, Boudreau M, Mahlen S. Evaluation of empiric antimicrobial therapy and resistance of catheter-associated urinary tract infections versus non-catheter associated urinary tract infections in a level II trauma center. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #12-055. *Encore presentation*: 35th Annual Eastern States Conference, Hersey, Pennsylvania, May 2015.

Lee J, **Casapao AM**, Marston M. Evaluation of empiric and definitive therapy for febrile neutropenia. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #2-119.

Wilson C, Graftam J, **Casapao AM**, Mahlen S. Evaluation of ceftolozane/tazobactam susceptibilities in *Pseudomonas aeruginosa* bloodstream isolates at level II trauma tertiary hospital. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #2-129.

Rusby M, Thorton L, Ng YT, **Casapao AM**. Pharmacoepidemiology of pediatric patients with bronchiolitis. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #2-125. *Encore presentations*: Pediatric Pharmacy Advocacy Group 25th Annual Conference, Atlanta, Georgia, May 2016; Abstract # 88 and 7th Annual Husson Research and Scholarship Day, Bangor, Maine, April 21, 2016; Abstract #O-6.

Tran K, **Casapao AM**. Pharmacoepidemiology of Enterobacter infections at a level two tertiary medical center. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #2-126.

Casapao AM, Jacobs DM, Bowers DR, Beyda NE, Dilworth TJ. Early Beta-Lactam Therapy Combined with Standard Therapy for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections compared to Standard Alone: A Multicenter, Retrospective, Propensity-Matched Analysis. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #B-071.

Rusby M, Wilson C, **Casapao AM**. Impact of Mortality and Source of Infection in Intermediate Risk Patients with *Staphylococcus aureus* Bacteremia. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #K815.

Wilson C, Rusby M, **Casapao AM**. Epidemiological Study of Obese Patients with *Staphylococcus aureus* Bacteremia at Eastern Maine Medical Center. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #K814.

Zasowski EJ, Claeys KC, **Casapao AM**, Sabagha N, Klinker KP, Davis SL, Rybak MJ. Ceftaroline fosamil for the Treatment of Methicillin-Resistant *Staphylococcus aureus* Pneumonia. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #B-081.

Zasowski EJ, Claeys KC, **Casapao AM**, Sabagha N, Klinker KP, Davis SL, Rybak MJ. Ceftaroline fosamil for the treatment of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #B-079.

Trafton M, **Casapao AM**, Seavey W, Boudreau M. Quasi-Experimental Study to Evaluate Drug Administration Complications with the Use of Extended Infusion Piperacillin/Tazobactam. 34th Annual Eastern States Conference, Hersey, Pennsylvania, May 2015.

Zasowski EJ, Lagnf AM, **Casapao AM**, Rybak MJ. Impact of Delayed Antibiotic Therapy on Outcomes of Patients with Hospital-Onset Enterococcal Bacteremia (EB): A Retrospective Cohort Study. 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2015; Abstract #eP163.

Pelletier J, **Casapao AM**. Analysis of Antimicrobial Therapy Optimization in Patients with *Escherichia coli* Bacteremia. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-6.

Nya P, **Casapao AM**. Evaluation of *Staphylococcus aureus* Bacteremia in Adults with Renal Disease. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-5.

Mehta, RM, **Casapao, AM**. The Impact of Erythromycin Resistance of Patients with *Staphylococcus aureus* Bacteremia. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-4.

Egharevba E, **Casapao, AM**. Infectious Diseases Consultation May Improve Treatment Outcome Associated with *Staphylococcus aureus* Bacteremia. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-2.

Akwuba V, **Casapao AM**. Clinical Outcomes of *Staphylococcus aureus* Bacteremia in Intravenous Drug Users. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-1.

Duron A, **Casapao AM**. Eastern Maine Medical Center Quality Improvement Review of Optimizing Ceftriaxone Therapy. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #O-6.

Rusby M, **Casapao AM**. Mortality Rates in Low-Risk, Intermediate-Risk, and High-Risk Patients. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #O-8.

Wilson C, **Casapao AM**. An Epidemiological Study of Obese Patients with Staphylococcus aureus Bacteremia at Eastern Maine Medical Center. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #O-9.

Casapao AM, Lagnf AM, Rybak MJ. Temporal Characterization of Patients with Enterococcal Bloodstream Infection. 2014 Division of Infectious Disease Annual Conference, Augusta, Maine, November 19, 2014.

Trafton M, Boudreau M, Seavey W, **Casapao AM**. A Quasi-Experimental Study to Evaluate Drug Administration Complication in the Use of Extended Infusion Piperacillin/Tazobactam. 49th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Anaheim, California, December 2014; Abstract #10-187.

Casapao AM, Lagnf AM, Rybak MJ. Temporal Characterization of Patients with Enterococcal Bloodstream Infection. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K1665.

Claeys KC, **Casapao AM**, Davis SL, Rybak MJ. Burden of Illness with Acute Bacterial Skin and Skin Structure Infections Evaluated in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K1702.

Nagel JL, Pogue J, Claeys KC, **Casapao AM**, Finks J, Rybak MJ. Utilization of the Centers for Disease Control and Prevention National Healthcare Safety Network Antimicrobial Use and Resistance Module to Compare Multicenter Antimicrobial Use. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K332.

Claeys KC, Nagel JL, **Casapao AM**, Pogue JM, Finks J, Davis SL, Rybak MJ. Implementing the National Healthcare Safety Network's Antimicrobial Use Option to Aid in Determination of Resistance Among Key Nosocomial Pathogens. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K327.

Nagel JL, Pogue JM, Claeys KC, **Casapao AM**, Finks J, Davis SL, Rybak MJ. Utilization of the Center for Disease Control Antimicrobial Use and Resistance Module to Compare Multicenter Antimicrobial Prescribing on Medical, Surgical, and Intensive Care Units. 17th Annual Making a Difference in Infectious Diseases Pharmacotherapy Meeting, Orlando, FL, May 2014.

Claeys KC, Nagel JL, Pogue JM, **Casapao AM**, Finks J, Davis SL, Rybak MJ. Implementing the National Healthcare Safety Network's Antibiotic Utilization and Resistance Program to Determine Resistance Among Key Nosocomial Pathogens. 17th Annual Making a Difference in Infectious Diseases Pharmacotherapy Meeting, Orlando, FL, May 2014.

Casapao AM, Davis SL, Barr VO, Goff DA, Kaye KS, Pogue JM, Rybak MJ. Retrospective Multi-Centre Experience of the Effectiveness and Safety with Ceftaroline Fosamil Therapy in Patients with Acute Bacterial Skin and Skin Structure Infections. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #eP422.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. The Effectiveness and Safety with Ceftaroline Fosamil Therapy for Lower Respiratory Tract Infections in a Retrospective Multi-Centre Study. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #eP425.

Claeys KC, **Casapao AM**, Pogue JM, Bhatia N, Mynatt RP, Saely S, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado Jr. G, Giuliano CA, Takla R Johnson LB, Davis SL, Rybak MJ. Rapid Diagnostic Testing with GeneXpert Improves Enrollment in a Randomised Clinical Trial for Detection of Methicillin-Resistant *Staphylococcus aureus* in Acute Bacterial Skin and Skin Structure Infections. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #P1471.

Bentley K, Epps K, Cannon C, **Casapao AM**, Tucker C. Evaluation of the Efficacy of Extended Infusion Piperacillin-Tazobactam Administration in Non-Intensive Care Unit Patients. 3rd Annual Florida Residency Conference and Florida Society of Health-system Pharmacists, Gainesville, FL May 2014.

Weissman A, Yiannos L, Ge, E, Mynatt RP, Rybak MJ, Millis S, **Casapao AM**, Levy P. A Retrospective Review of Empiric Antibiotic Selection in Patients Admitted with Urinary Tract Infection. 18th Annual New England Regional Society for Academic Emergency Medicine, New Haven, CT March 2014; Abstract #32A.

Weissman A, Yiannos L, Ge, E, Mynatt RP, Rybak MJ, Millis S, **Casapao AM**, Levy P. Appropriateness of Outpatient Empiric Antibiotic Selection in Patients with Urinary Tract Infections. 18th Annual New England Regional Society for Academic Emergency Medicine, New Haven, CT March 2014; Abstract #32.

Ni D, Rising K, **Casapao AM**, Barber KE, Mynatt RP, Rybak MJ. Vancomycin Consensus Guidelines Application and Serum Concentration Target Attainment. 48th ASHP Midyear Clinical Meeting Orlando, FL, December 2013; Abstract #1-316.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. Multicenter Experience of the Effectiveness and Safety with Ceftaroline Fosamil (CPT) Therapy. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #20.

Claeys KC, **Casapao AM**, Goff DA, Kaye KS, Levine DP, Davis SL, Rybak MJ. Daptomycin versus Vancomycin for Bloodstream Infection caused by Methicillin-Resistant *Staphylococcus aureus* (MRSA) Preliminary Results. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #68.

Claeys KC, **Casapao AM**, Pogue JM, Bhatia N, Mynatt RP, Saely S, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Johnson LB, Davis SL, Rybak MJ. Characterization of Patients Treated for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Documented or at Risk of Methicillin-Resistant *Staphylococcus aureus* (MRSA). 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #67.

Ni D, Rising K, **Casapao AM**, Barber KE, Mynatt RP, Rybak MJ. Vancomycin Consensus Guidelines Application and Serum Concentration Target Attainment. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #35.

Divekar P, **Casapao AM**, Firestone SM, Rybak MJ, Martin ET. Comparative Study of Prevalence of pSK41 in Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA) Isolates Against non-hVISA Isolates. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #75.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. Multicenter Experience of the Effectiveness and Safety with Ceftaroline Fosamil (CPT) Therapy. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, September 10-13, 2013; Abstract # K-192.

McRoberts JP, **Casapao AM**, Lephart PR, Rybak MJ. Evaluation of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bloodstream Infections (BSI) Minimum Inhibitory Concentrations (MICs) to Vancomycin (VA) and Daptomycin (DAP) at an Urban Detroit Medical Institution. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, September 10-13, 2013; Abstract # C2-080.

Casapao AM, Davis SL, Levine DP, Rybak MJ. Characterization of Patients with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, September 10-13, 2013; Abstract # K-1285.

Casapao AM, Davis SL, Kullar R, Patel S, Levine DP, Rybak MJ. An Alternative Susceptibility Method as Predictor of Clinical Response to Vancomycin (VAN) with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 21st Annual Infectious Diseases Pharmacotherapy Fellowship Forum, York Harbor, ME, May 2013; Abstract #10.

Casapao AM, Davis SL, Kullar R, Patel S, Levine DP, Rybak MJ. An Alternative Susceptibility Method as Predictor of Clinical Response to Vancomycin (VAN) with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 12th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, International Society of Cardiovascular Infectious Diseases (ISCVID), Dubronik, Croatia, May 2013; Abstract # P41.

Casapao AM, Barber KE, Wong CK, Barr V, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Clinical experience with ceftaroline fosamil (CPT) for bloodstream infections (BSI). 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 2013; Abstract # 3369.

Casapao AM, Patel S, Kullar R, Davis SL, Levine DP, Rybak MJ. Evaluation of vancomycin exposure on outcomes in a cohort of patients with methicillin-resistant *Staphylococcus aureus* (MRSA) infective endocarditis (IE). 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 2013; Abstract # 2655.

Casapao AM, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Early Experience with Ceftaroline fosamil Therapy at an Academic Hospital System. 9th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2012; Abstract #10.

Barber KE, Pogue JM, **Casapao AM**, Rybak MJ. Outcomes Associated with Vancomycin Intermediate *Staphylococcus aureus* (VISA) Bloodstream Infections (BSI). 9th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2012; Abstract #43.

Casapao AM, Patel S, Kullar R, Davis SL, Rybak MJ. Evaluation of Population Analysis Profile Susceptibility (PAP) as a Predictor of Patient Outcomes with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-946.

Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. High-Dose Daptomycin for Treatment of Enterococcal Infections: Multicenter, Retrospective Study. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-275.

Barber KE, **Casapao AM**, Pogue JM, Kaye KS, Rybak MJ. Outcomes Associated with Vancomycin Intermediate *Staphylococcus aureus* (VISA) Bloodstream Infections (BSI). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-906.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-1123.

Casapao AM, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Early Experience with Ceftaroline fosamil Therapy at an Academic Hospital System. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-909.

Martin ET, **Casapao AM**, McRoberts J, Archer C, Kaye KS, Rybak MJ. Low prevalence of Inc18-like *vanA* plasmid among prospectively-collected vancomycin-resistant *Enterococcus* isolates from Detroit Medical Center. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #C2-1985.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA). Star of the North 20th Annual Infectious Diseases Pharmacotherapy Fellowship Forum, Brainerd, MN, June 2012.

Casapao AM, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Ceftaroline fosamil Therapy for *Staphylococcus aureus* Infections. 15th Making A Difference in Infectious Diseases Pharmacotherapy, Orlando, FL, March 2012; Abstract #5-OR FRS.

Kasha MZ, Barber KE, **Casapao AM**, Mynatt RP, Rybak MJ. Vancomycin Consensus Guidelines Application and Serum Concentration Target Attainment: A Quality Assessment Evaluation. 46th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, New Orleans, LA, December 2011; Abstract #4-157.

Casapao AM, Kullar R, Leonard SN, Davis SL, Kaatz GW, Patel N, Lodise TP, Goff DA, Potoski BA, LaPlante KL, Rybak MJ. Clinical Outcomes in Patients with Vancomycin Heteroresistant *Staphylococcus aureus*. 8th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2011; Abstract #61.

Casapao AM, Potoski BA, Doi Y, Pasculle AW. *In vitro* susceptibilities of Fosfomycin against Enterobacteriaceae producing KPC-type Beta-lactamases. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, September 17-20, 2011; Abstract #E-725.

Armahizer MJ, **Casapao AM**, Potoski BA. Persistent Bacteremia in a patient due to Vancomycin-Intermediate *Staphylococcus aureus* (VISA). 45th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2010; Abstract #6-150.

Casapao AM, Stafford L, Loudy M, Epps K. Extended Infusion Beta-Lactam Antibiotic Administration in Critically Ill Adult Patients. 41st Southeastern Residency Conference, Athens, GA, April 29-30 2009.

Casapao AM, Stafford L, Loudy M, Epps K. Extended Infusion Beta-Lactam Antibiotic Administration in Critically Ill Adult Patients. 44th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 2009; Abstract #7-125.

Research Platform Presentations

Casapao AM, Davis SL, Kullar R, Levine DP, Rybak MJ. An Alternative Susceptibility Method as Predictor of Clinical Response to Vancomycin (VAN) with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis. 21st Annual Infectious Diseases Pharmacotherapy Fellowship Forum, York Harbor, ME, May 2013; Abstract #10.

Casapao AM, Patel S, Kullar R, Davis SL, Levine DP, Rybak MJ. Evaluation of vancomycin exposure on outcomes in a cohort of patients with methicillin-resistant *Staphylococcus aureus* (MRSA) infective endocarditis (IE). 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 29, 2013; Abstract #2655.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-1123.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA). Star of the North 20th Annual Infectious Diseases Pharmacotherapy Fellowship Forum, Brainerd, MN, June 2012; Abstract #21.

Casapao AM, Stafford L, Loudy M, Epps K. Extended Infusion Beta-Lactam Antibiotic Administration in Critically Ill Adult Patients. 41st Southeastern Residency Conference, Athens, GA, April 29-30 2009.

Research Posters

Kunz Coyne AJ, **Casapao AM**, Isache C, Morales J, McCarter YS, Jankowski CA. Influence of antimicrobial stewardship and molecular rapid diagnostic test on antimicrobial prescribing for extended-spectrum beta-lactamase and carbapenemase-producing bacteria in bloodstream infections. 9th Annual IDweek Meeting, October 2020.

Carr A, Minor S, El Ghali, Kaur P, **Casapao AM**. Early real-world evidence in the use of eravacycline therapy for the management of draconian infections. 9th Annual IDweek Meeting, October 2020.

Venugopalan V, Hernandez S, DeSear K, Peloquin C, Cherabuddi K, **Casapao AM**. Use of therapeutic drug monitoring to optimise cephazolin dosing in the treatment of methicillin-susceptible *Staphylococcus aureus* bacteremia. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 2020; Abstract #2657.

Nilles L, Pirasteh A, Sothoron C, Tucker C, **Casapao AM**. Effectiveness of Using Oral Vancomycin as Prophylaxis for *Clostridium difficile* Infections in High-Risk Patients. Florida Residency Conference, Tampa, Florida, May 2019. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 2020; Abstract #3676.

Casapao AM, Mahlen SD. Evaluation of Ceftaroline and Telavancin Susceptibilities against Enterococcal Bloodstream Isolates. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #4328.

Casapao AM, Wungwattana M. The landscape of *Pseudomonas aeruginosa* clinical isolates in rural Northeastern United States and the Potential Impact on Hospital Mortality. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #7097.

Casapao AM, Mahlen SD. Ceftazidime-avibactam and ceftolozane-tazobactam activity against *Escherichia coli* producing CTX-M beta-lactamases. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #5215.

Casapao AM, Grieser H, Meak S, Matluck N. Clinical Impact of Further Laboratory Diagnosis for Carbapenem Resistant Enterobacteriaceae. Maine Center for Disease Control and Prevention 2016 Division of Infectious Disease Annual Conference, Augusta, Maine, November 16, 2016; Abstract #5.

Casapao AM, Jacobs DM, Bowers DR, Beyda NE, Dilworth TJ. Early Beta-Lactam Therapy Combined with Standard Therapy for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections compared to Standard Alone: A Multicenter, Retrospective, Propensity-Matched Analysis. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2014; Abstract #B-071.

Casapao AM, Lagnf AM, Rybak MJ. Temporal Characterization of Patients with Enterococcal Bloodstream Infection. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K-1665.

Casapao AM, Davis SL, Barr VO, Goff DA, Kaye KS, Pogue JM, Rybak MJ. Retrospective Multi-Centre Experience of the Effectiveness and Safety with Ceftaroline Fosamil Therapy in Patients with Acute Bacterial Skin and Skin Structure Infections. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #eP422.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. The Effectiveness and Safety with Ceftaroline Fosamil Therapy for Lower Respiratory Tract Infections in a Retrospective Multi-Centre Study. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #eP425.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. Multicenter Experience of the Effectiveness and Safety with Ceftaroline Fosamil (CPT) Therapy. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #20.

Casapao AM, Barber KE, Wong CK, Barr V, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Clinical experience with ceftaroline fosamil (CPT) for bloodstream infections (BSI). 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013; Abstract # 3369.

Casapao AM, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Early Experience with Ceftaroline fosamil Therapy at an Academic Hospital System. 9th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2012; Abstract #10.

Casapao AM, Patel S, Kullar R, Davis SL, Rybak MJ. Evaluation of Population Analysis Profile Susceptibility (PAP) as a Predictor of Patient Outcomes with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 2012; Abstract #K-946.

Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. High-Dose Daptomycin for Treatment of Enterococcal Infections: Multicenter, Retrospective Study. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 2012; Abstract #K-275.

Casapao AM, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Early Experience with Ceftaroline fosamil Therapy at an Academic Hospital System. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-909.

Casapao AM, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Ceftaroline fosamil Therapy for *Staphylococcus aureus* Infections. 15th Making A Difference in Infectious Diseases Pharmacotherapy, Orlando, FL, March 2012; Abstract #5-OR FRS.

Casapao AM, Kullar R, Leonard SN, Davis SL, Kaatz GW, Patel N, Lodise TP, Goff DA, Potoski BA, LaPlante KL, Rybak MJ. Clinical Outcomes in Patients with Vancomycin Heteroresistant *Staphylococcus aureus*. 8th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2011; Abstract #61.

Casapao AM, Potoski BA, Doi Y, Pasculle AW. *In vitro* susceptibilities of Fosfomycin against Enterobacteriaceae producing KPC-type Beta-lactamases. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, September 17-20, 2011; Abstract #E-725.

Armahizer MJ, **Casapao AM**, Potoski BA. Persistent Bacteremia in a patient due to Vancomycin-Intermediate *Staphylococcus aureus* (VISA). 45th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2010; Abstract #6-150.

Casapao AM, Stafford L, Loudy M, Epps K. Extended Infusion Beta-Lactam Antibiotic Administration in Critically Ill Adult Patients. 44th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 2009; Abstract #7-125.

Journal/Grant Peer Reviewer

BMC Infectious Diseases
Patient-Centered Outcomes Restitute Institute (PCORI)
Infectious Diseases and Therapy
Clinical Therapeutics
PLOS ONE
Pharmacotherapy
Annals of Pharmacotherapy (DICP)
Antimicrobial Agents Chemotherapy
Clinical Infectious Diseases
American Journal of the Medical Sciences
Infection Control and Hospital Epidemiology
F1000 Medicine Reports

Teaching Experience

Professional Practice Skills Lab III (PHA5163L). University of Florida College of Pharmacy Jacksonville Campus. P2 PharmD Candidates. Campus Facilitator. Fall 2019 and 2020.

Principles of Medical Microbiology, Immunology & Virology (PHA5755). University of Florida College of Pharmacy. P2 PharmD Candidates. Course Leader, Instructor, Lecturer, and Facilitator. Summer 2018-2020 and Fall 2018-2020.

Foundations of Clinical Practice Course (PHA5956). University of Florida College of Pharmacy. P4 PharmD Candidates. Instructor and Facilitator. Summer 2020.

Pharmacotherapy and Translational Research Elective (PHA5907). University of Florida College of Pharmacy. P2 and P3 PharmD Candidates. Course Leader, Instructor, Lecturer, and Facilitator. Fall 2018-2019 and Spring 2020,

Advanced Topics in Infectious Disease (PHA5605). University of Florida College of Pharmacy. P3 PharmD Candidates. Course Leader, Instructor, Lecturer, and Facilitator. Spring 2018-2020.

Advanced Pharmacy Practice Experiential Readiness (PHA5759). University of Florida College of Pharmacy Jacksonville Campus. P3 PharmD Candidates. Campus Facilitator. Spring 2018-2020.

Professional Practice Skills Lab VI (PHA5166L). University of Florida College of Pharmacy Jacksonville Campus. P3 PharmD Candidates. Campus Facilitator. Spring 2018-2020.

Personal and Professional Development (PHA5702C). University of Florida College of Pharmacy Jacksonville Campus. P3 PharmD Candidates. Campus Facilitator. Spring 2018-2020.

Professional Practice Skills Lab V (PHA5165L). University of Florida College of Pharmacy Jacksonville Campus. P3 PharmD Candidates. Campus Facilitator. Fall 2017-19.

Professional Practice Skills Lab I (PHA5161L). University of Florida College of Pharmacy Jacksonville Campus. P1 PharmD Candidates. Campus Facilitator. Fall 2017 and 2019.

Pharmacy Residency Application Preparation Workshop Series. University of Florida College of Pharmacy. P2 and P3 PharmD Candidates. Instructor and Lecturer. Spring 2019.

Professional Practice Skills Lab II (PHA5162L). University of Florida College of Pharmacy Jacksonville Campus. P1 PharmD Candidates. Campus Facilitator. Spring 2019.

History of Pharmacy (PHA5020). University of Florida College of Pharmacy Jacksonville Campus. P3 PharmD Candidates. Campus Facilitator. Winter 2017.

Infectious Diseases Pharmacotherapy Elective (RX 569). Husson University School of Pharmacy. P3 PharmD Candidates. Course Coordinator/Lecturer/Facilitator. Fall 2016 and 2017.

Infectious Diseases Research (RX 490). Husson University School of Pharmacy. P1, P2, and P3 PharmD Candidates. Course Coordinator/Lecturer. Spring 2015, Summer 2015, Fall 2015, Summer 2016, Fall 2016, Spring 2017, Summer 2017, and Fall 2017.

Advanced Pharmacy Practice Experience (RX611) Infectious Diseases Clinical Clerkship Rotation. Husson University School of Pharmacy/Eastern Maine Medical Center. P4 PharmD Candidates. Preceptor (5 days for 6 weeks) and Course Coordinator: Fall 2014, Spring 2015, Summer 2015, Fall 2015, Winter 2016, Spring 2016, Summer 2016, Fall 2016, Winter 2017, and Spring 2017.

Pharmacy Capstone (RX542). Husson University School of Pharmacy. P3 PharmD Candidates. Course Coordinator/Lecturer. Spring 2015, 2016, and 2017.

Pharmacotherapeutics I (RX474). Husson University School of Pharmacy. P2 PharmD Candidates. Lecturer. Introduction and Review of Antimicrobial Agents, Pharmacokinetics of Vancomycin and Aminoglycosides. Spring 2016 and 2017.

Medical Microbiology (RX342). Husson University School of Pharmacy. P1 PharmD Candidates. Lecturer. Spring 2015, 2016, and 2017.

Pharmacotherapeutics III (RX522). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Sexual Transmitted Infections, Urinary Tract Infections and Meningitis. Spring 2017.

Applied Pharmacotherapeutics II Recitation (RX592). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer/Facilitator. Sexual Transmitted Infections and Meningitis. Spring 2015, 2016 and 2017.

Introductory Pharmacy Practice Experiential (RX550) Infectious Diseases Research. Husson University School of Pharmacy/Eastern Maine Medical Center. P3 PharmD Candidates. Preceptor (5 days for 3 weeks) Winter 2015, 2016, and 2017.

Principals of Pharmacokinetics (RX433). Husson University School of Pharmacy. P2 PharmD Candidates. Lecturer. Fall 2015 and 2016.

Applied Pharmacotherapeutics I Recitation (RX591). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Pneumonia and Infective Endocarditis. Fall 2016.

Pharmacotherapeutics II (RX521). Husson University School of Pharmacy. P3 PharmD Candidates. Lower respiratory tract Infections and Infective Endocarditis. Fall 2016.

NAPLEX Live Review Session. Husson University School of Pharmacy. Recent P4 PharmD graduates. Lecturer. Infectious Diseases Pharmacotherapy Review. Summer 2015 and 2016.

PGY2 Infectious Diseases Microbiology Rotation. Eastern Maine Medical Center. PGY-2 Infectious Disease Residency. Preceptor (5 days for 2 weeks) Summer 2016.

PGY1 Infectious Diseases Clinical Rotation. Eastern Maine Medical Center. PGY-1 Pharmacy Practice Residency. Preceptor (5 days for 4 weeks) Winter 2015, Spring 2015, and Summer 2016. Co-Preceptor (2-3 days for 4 weeks) Fall 2016 and Spring 2017.

Critical Care Pharmacotherapy (RX582). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Antimicrobial Therapy Considerations in Critically Ill Population. Spring 2016.

Drug-Drug Interactions (RX564). Husson University School of Pharmacy. P2 and P3 PharmD Candidates. Lecturer. Gastrointestinal Drug-Drug Interactions. Spring 2015 and 2016.

Drug Action VI (RX522). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Sexual Transmitted Infections and Meningitis. Spring 2015 and 2016.

Cognitive, Communication, and Case-Based Critical Thinking IV (RX432). Husson University School of Pharmacy. P2 PharmD Candidates. Lecturer/Facilitator. Spring 2015 and 2016.

Advanced Pharmacy Practice Experience (RX617) Pharmacy Research in Infectious Diseases Rotation. Husson University School of Pharmacy/Eastern Maine Medical Center. P4 PharmD Candidates. Preceptor (5 days for 6 weeks) Fall 2015 and Fall 2016.

Pharmacy Seminar (RX551). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Drug Literature Evaluation. Fall 2014 and 2015.

Applied Pharmacotherapeutics I Recitation (RX591). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Introduction and Review of Antimicrobial Agents, Pharmacokinetics of Vancomycin and Aminoglycosides, Pneumonia, Infective Endocarditis, and Urinary Tract Infections. Fall 2014 and 2015.

Drug Action V (RX521). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Introduction and Review of Antimicrobial Agents, Pharmacokinetics of Vancomycin and Aminoglycosides, Pneumonia, Infective Endocarditis, and Urinary Tract Infections. Fall 2014 and 2015.

Geriatric Pharmacotherapy Elective (RX490.001). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Respiratory, Renal, and Urological Disorders in Elderly Population. Summer 2014.

PGY2 Infectious Diseases Consult Rotation. Detroit Receiving Hospital. PGY-2 Residency. Co-Preceptor (5 days for 4 weeks) Fall 2011, 2012, and 2013.

Principles of Pharmacotherapy 3 (PHA 4210) – Respiratory and Infectious Diseases Pharmacotherapy. Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences. P2 PharmD Candidates. Lecturer. Skin and Soft Tissue Infections and Surgical Prophylaxis. Winter 2012 and 2013.

Pharmacotherapy Problem Solving (PHA 5270). Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences. P3 PharmD Candidates. Co-Facilitator (1 day/week) Spring 2012.

Advanced Pharmacy Practice Patient Care Elective (APPE) (PPR7530): Infectious Diseases Consult Rotation. Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences/Detroit Receiving Hospital. P4 PharmD Candidates. Co-Preceptor (5 days for 6 weeks) Fall 2011, Spring 2012, and Fall 2012.

Directed Study in Pharmacy Practice (PPR 7990). Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences. P2 PharmD Candidates. Co-Facilitator. Summer 2012 and 2013.

PGY1 Infectious Diseases Consult Rotation. University of Pittsburgh Medical Center-Presbyterian Hospital. PGY-1 Residency. Co-Preceptor (5 days for 4 weeks) Spring 2011.

Advanced Pharmaceutical Care 2 (PHARM 5321). University of Pittsburgh School of Pharmacy. P3 PharmD Candidates. Facilitator. Spring 2011.

Pharmacotherapy of Infectious Diseases 2 (PHARM 5215). University of Pittsburgh School of Pharmacy. P2 PharmD Candidates. Lecturer. Introduction to Mycoses. Spring 2011.

Pharmacotherapy of Infectious Diseases 2 (PHARM 5215). University of Pittsburgh School of Pharmacy. P2 PharmD Candidates. Lecturer. Candidiasis. Spring 2011.

Advanced Pharmaceutical Care 1 (PHARM 5225). University of Pittsburgh School of Pharmacy. P2 PharmD Candidates. Facilitator. Spring 2011.

Profession of Pharmacy 2 (PHARM 5111). University of Pittsburgh School of Pharmacy. P1 PharmD Candidates. Facilitator. Spring 2011.

Pharmacotherapy of Gastroenterology/Nutrition (PHARM 5223). University of Pittsburgh School of Pharmacy. P2 PharmD Candidates. Facilitator. Spring 2011.

Pharmacotherapy of Cardiovascular Diseases (PHARM 5216). University of Pittsburgh School of Pharmacy. P2 PharmD Candidates. Facilitator. Fall 2010.

Profession of Pharmacy 1 (PHARM 5110). University of Pittsburgh School of Pharmacy. P1 PharmD Candidates. Facilitator. Fall 2010.

Advanced Pharmacy Practice Experience (APPE) 2 (PHARM 5402) Infectious Diseases Consult Rotation. University of Pittsburgh School of Pharmacy/University of Pittsburgh Medical Center-Presbyterian Hospital. P4 PharmD Candidates. Co-Preceptor (5 days for 4 weeks) Fall 2010.

APPE Drug Information Rotation. St. Vincent's Medical Center/University of Florida College of Pharmacy. P4 PharmD Candidate. Co-Preceptor (5 days for 4 weeks) Winter 2009.

APPE Infectious Diseases Rotation. St. Vincent's Medical Center/Florida Agricultural and Mechanical University College of Pharmacy and Pharmaceutical Sciences. P4 PharmD Candidate. Co-Preceptor (5 days for 4 weeks) Fall 2009.

Pharmaceuticals Skills Laboratory (PHA 5108L). University of Florida College of Pharmacy. P3 PharmD Candidates. Facilitator. Fall 2009.

Platform Presentations

Antibiotic Use Dogma: The Struggle between Preservation and Abuse. 2019
Presented to students and faculty at Jacksonville University. Science and Engineering Lectures Series at Jacksonville University, Jacksonville, Florida.

Developing Diplomatic PharmaLeaders for the 21st Century: Leading to Leave a Legacy. 2019
Presented to Academic Faculty and Pharmacists. American Association of Colleges of Pharmacy (AACCP) INVOLVE 2019 Interim Meeting, Tampa, Florida.

Research & Academia are the JAM! I'm so sure it's the future of pharmacy! 2019
Presented to Pharmacy Student Leaders and faculty at the University of Florida College of Pharmacy. Student Organization Annual Retreat (SOAR), Jacksonville, Florida.

Antibiotic Stewardship Best Practices with Q&A 2018
Presented Webinar to Pharmacists, Nurses, and Healthcare providers with Health Care-Associated Infection Program and Florida Department of Health and Health

Achieving Optimal Health Outcomes through Outpatient Antimicrobial Stewardship 2017
Presented CE to Pharmacists & Technicians at regional Maine Society Health-System Pharmacists UAN# 0837-9999-17-038-L01-P/T

Antimicrobial Stewardship: Advancing Patient Care by Improving Medication Use 2017
Presented CE to Pharmacists & Technicians at regional Maine Pharmacy Association UAN# 0837-9999-17-030-L01-P/T

The Rise of Antimicrobial Resistance and Antimicrobial Stewardship 2016
Presented CE to Pharmacists, Physicians, Nurses, Technicians at regional Maine CDC

Age of New Antimicrobials: Novelty versus Imitation 2015
Presented CE credit to Pharmacists, Pharmacy students and technicians at regional MSHP

UAN#0837-9999-15-137-LO1-P/T

<i>Clinician's Guide to Optimizing Beta-Lactams through Extended Infusion</i> Presented CE credit to Pharmacists and Pharmacy technicians	2011
<i>Drug Therapy Management of Clostridium difficile- Associated Diarrhea. Guideline Protocol and Order Set.</i> Presented to Pharmacy and Therapeutics Committee.	2011
<i>In vitro Susceptibilities of Fosfomycin against Enterobacteriaceae Producing KPC- Type Beta-Lactamases</i> Presented to ID grand rounds to ID physicians, fellows, medical residents Presented to clinical pharmacists, preceptors, and pharmacy students	2011
<i>Novel Daptomycin Combination against Daptomycin-Nonsusceptible Methicillin Resistant Staphylococcus aureus. Journal Club.</i> Presented to ID physicians, preceptors, fellows, and medical residents	2011
<i>Impact of Early Oseltamivir Treatment on Outcome in Critically ill Patients with 2009 Pandemic Influenza A. Journal Club.</i> Presented to clinical pharmacists, preceptors, pharmacy residents and students	2011
<i>Principles of Antibiotics</i> Monthly lecture presented to medical residents and students at UPMC	2011
<i>Rapid Identification for Methicillin-Resistant Staphylococcal aureus Bacteremia. ID Grand Rounds Puzzler.</i> Presented to ID physicians, fellows, medical residents and students	2011
<i>Therapeutic Drug Monitoring of Linezolid. Journal Club.</i> Presented to clinical pharmacists, preceptors, pharmacy residents and students	2010
<i>Infective Endocarditis: Adjunctive Use of Ceftriaxone for the Treatment of Enterococcus Faecalis</i> Presented to pharmacy residents, preceptors, students and faculty	2010
<i>Bugs & Drugs: The Rise of Gram Negative Bacteria</i> UAN: 0077-9999-10-014-L01-P; UPN: 0012-0000-10-074-H01-P Presented CE credit to physicians, pharmacists, nurses, and medical technologists	2010
<i>Urinary Tract Infections in the Community Setting</i> Presented to medical residents and attending physicians	2010
<i>Preventative Medicine and Health Maintenance</i> Presented to pharmacy residents, preceptors, students and faculty	2010
<i>Carbapenem MUE and Drug Class Review</i> Presented to pharmacy and therapeutics committee and medical executive committee	2010
<i>Human Papillomavirus Virus Update</i> Presented to pharmacy residents, preceptors, students and faculty	2010

<i>Proper Use of Antibiotics In-Service</i> Presented to family medicine residents and physicians	2009
<i>Clinical Trial Jeopardy</i> Presented to pharmacy residents, preceptors, students and faculty	2009
<i>Cold and Cough Evidence Base Medicine Review</i> Presented to pharmacy residents, preceptors, students and medical residents	2009
<i>Drug Induced Nephrotoxicity</i> Presented to pharmacy residents, preceptors, students and faculty	2009
<i>Beta-Lactam Dose Optimization in Critical Care Units In-Service</i> Presented to pharmacists, physicians and nurses at St. Vincent's Medical Center	2009
<i>Microsoft Excel and Data Collection</i> Presented to pharmacy residents, preceptors, students and faculty	2009
<i>Prerenal Nephrotoxicity</i> Presented to pharmacy residents, preceptors, students and faculty	2009
<i>Dronedarone In-Service</i> Presented to nurses at St. Vincent's Medical Center	2009
<i>Update on H1N1 2009</i> Presented to pharmacy residents, preceptors, students and faculty	2009
<i>Case Presentation: Septic Arthritis</i> Presented to pharmacy residents, preceptors, students and faculty	2009

Leadership Activities

<i>Diversity and Inclusion Taskforce</i> University of Florida College of Pharmacy	July – Present
<i>Curriculum Committee</i> University of Florida College of Pharmacy	August 2018 – Present
<i>Associate Editor</i> Harvard Public Health Review	March 2017–December 2017
<i>American Pharmacists Association Advisor</i> Husson University School of Pharmacy	February 2017–October 2017
<i>HAI Collaborating Partners Committee</i> Maine Center for Disease Control and Prevention	July 2015–October 2017
<i>Medication Management Committee</i> Eastern Maine Health System	September 2014–October 2017
<i>Antimicrobial Stewardship Committee</i> Eastern Maine Medical Center	September 2014–October 2017

Infection Prevention and Control Function Team Eastern Maine Medical Center	September 2014–October 2017
<i>Assessment Committee</i> Husson University School of Pharmacy	August 2014–May 2016
<i>Internet Committee</i> Society of Infectious Diseases Pharmacists (SIDP)	September 2014– August 2015
<i>Recognition Awards Committee</i> Society of Infectious Diseases Pharmacists (SIDP)	September 2012– August 2014
<i>Interorganizational Committee</i> Society of Infectious Diseases Pharmacists (SIDP)	September 2011– August 2012
<i>Organization Affairs Council</i> Florida Society of Health-System Pharmacists (FSHP) Establish a plan for membership development and retention including special membership benefits and promotions to target groups. Organize the FSHP Professional Policy and Procedure Manual.	2009 – 2010
<i>Electronic Mentor</i> Wingate University School of Pharmacy Respond to questions specific to practice, interests and passions while allowing first year pharmacy students to learn from the insight and real-world experiences of multiple mentors.	2009 – 2014
<i>Student Forum Membership Advisory Group</i> National Student Forum of ASHP Promoted student membership by highlighting the value of ASHP. Evaluated current student member benefits and services. Promoted careers in health-system pharmacy and disseminated health system information	2007 – 2008
<i>ASHP-Student Society President</i> Wingate University School of Pharmacy	2007 – 2008
<i>Professionalization Committee Student Representative</i> Wingate University School of Pharmacy Deliberated on student honors and awards and developed an annual special activity calendar of professional opportunities.	2007 – 2008
<i>ASHP-Student Society Liaison</i> Wingate University School of Pharmacy Promoted involvement in professional service activities to enhance student professionalism and support the university and community.	2005 – 2007
<i>Class Treasurer</i> Midwestern University College of Health Science Initiated fundraisers to assist professionalism and budgeted Midwestern University Biomedical Science Program funds.	2003 – 2004

Professional Associations

American Association of Colleges of Pharmacy (AACP)	2014 – Present
European Society of Clinical Microbiology and Infectious Diseases	2012 – Present
Society of Infectious Diseases of Infectious Diseases of Pharmacists (SIDP)	2011 – Present
Infectious Diseases Society of America (IDSA)	2011 – Present
American College of Clinical Pharmacy (ACCP)	2005 – Present
American Society for Microbiology (ASM)	2011 – 2016
Pennsylvania Society of Health-System Pharmacist (PSHP)	2010 – 2011
American Society of Health-System Pharmacist (ASHP)	2005 – 2010
Florida Society of Health-System Pharmacist (FSHP)	2009 – 2010
North Carolina Association of Pharmacists (NCAP)	2005 – 2009
American Pharmacists Association (APhA)	2005 – 2008

Funded Research Grants

Casapao AM. Co-Investigator. Predictors of sub-therapeutic beta-lactam serum concentrations in the acute phase of septic shock. University of Florida Health Sciences Center Dean's Fund Research Award. (\$10,000 12/01/2019-present).

Casapao AM. Co-Investigator. Accuracy and Reliability of Finger Stick Capillary Blood Sampling for Therapeutic Drug Monitoring of Vancomycin Levels and Basic Metabolic Profile. University of Florida Health Science Center Dean's Fund Research Award. (\$5,000 04/01/2018-12/31/2019).

Casapao AM. Principal Investigator. Impact of Antimicrobial Use for the Management of for the Management of Hospital acquired Pneumonia and Ventilator associated Pneumonia: A Time Series Analysis of the Infectious Diseases Society of America and American Thoracic Society Publication of Clinical Practice Guidelines. 2017 IDSA Education and Research Foundation Young Investigator Award in Infectious Diseases. Proposal submitted and Funding denied.

Casapao AM. Principal Investigator. Impact of Delaying Antibiotic Prescriptions for Patients with Chronic Obstructive Pulmonary Disease: Antimicrobial Stewardship Initiative. NACDS Foundation. Proposal submitted and Funding denied.

Casapao AM. Co-Investigator. Development and Implementation of Intramural Comprehensive Examination for P2s. Intramural Husson University School of Pharmacy. (\$3,825 01/01/2017-12/31/2017).

Casapao AM. Co-Investigator. Pharmacoepidemiology of Antimicrobial Therapy Optimization in Patients with Escherichia coli Bloodstream Infection. Intramural Husson University School of Pharmacy. (\$3,500 07/01/2016-06/30/2016).

Casapao AM. Co-Investigator. Oritavancin Assay Development continuation. Intramural Husson University School of Pharmacy. (\$3,000 07/01/2016-06/30/2016).

Casapao AM. Co-Investigator. Oritavancin Assay Development Pilot Study. Intramural Husson University School of Pharmacy. (\$4,000 07/01/2015-06/30/2016).

Casapao AM. Co-Investigator. Characterization of the Treatment of Candiduria. Astellas Pharma US, Inc. (\$62,614 01/01/2015-12/31/2015).

Casapao AM. Principal Investigator. Ten Year Epidemiology Report of *Staphylococcus aureus* Infections in State of Maine. American Association of Colleges of Pharmacy. Protocol submitted and Funding denied.

Casapao AM. Principal Investigator. Impact of Early Beta-Lactam Therapy in Combination with Standard Therapy for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. Intramural Husson University School of Pharmacy. (\$8,000 07/01/2014-06/30/2016).

Casapao AM. Co-Investigator. Patient Outcomes Burden of Illness with Lower Respiratory Infections in Intensive Care Units. Cubist Pharmaceuticals Inc. (\$151,996 08/01/2014-07/31/2016).

Casapao AM. Co-Investigator. Cost-Analysis of Rapid Identification with Nanosphere Verigene Blood Culture Assay in Patients with Suspected Gram-Positive Bacteremia. Nanosphere. Protocol submitted and Funding denied.

Casapao AM. Co-Investigator. Impact of Early Daptomycin versus Vancomycin Therapy for Bloodstream Infection Caused by Methicillin-Resistant *Staphylococcus aureus*. Cubist Pharmaceuticals Inc. (\$177,792.50 02/01/2013-02/01/2015)

Casapao AM. Co-Investigator. A Retrospective, Comparative Evaluation of Acute Bacterial Skin and Skin Structure Infections Receiving Ceftaroline or Vancomycin. Forest Research Institute. Protocol submitted and Funding denied.

Casapao AM. Co-Investigator. Clinical and Economic Outcomes of Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections with Documented or at Risk of Methicillin-Resistant *Staphylococcus aureus*. Forest Research Institute. (\$254,310.00 04/01/2012-04/30/2014)

Casapao AM. Co-Investigator. Antimicrobial Use and Resistance (AUR) Option. National Healthcare Safety Network (NHSN) and Michigan Department of Community Health (MDCH). (\$223,491.24 08/01/2011-07/31/2013)

Casapao AM. Co-Investigator. High-Dose Daptomycin for Enterococcal Infections; A multi-center evaluation. Cubist Pharmaceuticals. (\$134,750.00 6/01/10-10/31/12)

Honors and Awards

Williams F. Beardsley Teaching Excellence Award – Husson University	2017
P4 Teacher of the Year – Husson University School of Pharmacy	2017
Distinguished Research Award – Husson University	2016
Intramural Husson University School of Pharmacy Research Grant	2014/2015/2016/2017
24 th ECCMID Travel Grant	2014
16 th MAD-ID Travel Grant	2013
23 rd ECCMID Travel Grant	2013
52 nd ICAAC Post-Doctoral Travel Grant	2012
15 th MAD-ID Travel Grant	2012
51 st ICAAC ID Fellows Grant	2011
Cum Laude, Wingate University School of Pharmacy	2009
Inducted into Phi Lambda Sigma	2007
Magna Cum Laude, Midwestern University	2005

Licensures and Certifications

Board Certified Infectious Diseases Pharmacist – BCIDP	2018 – Present
Registered Pharmacist, State of Florida Board of Pharmacy	2009 – Present
Registered Pharmacist, Commonwealth of Pennsylvania State Board of Pharmacy	2011– 2018
Registered Pharmacist, State of Maine Board of Pharmacy	2014 – 2017

References are available upon request